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Purpose: Patients who have failing infrainguinal bypass grafts or failed grafts reopened 
with lyric therapy represent a group at high risk of subsequent failure. Previous tudies 
suggest that vein patch angioplasty and jump grafting may be less durable than interpo- 
sition graft~ gas a method of correcting raft lesions. Our objective was to assess the value 
of various technical strategies for graft revision in a series of autogenous infrainguinal 
bypass grafts and to assess how these variables might affect cumulative graft patency 
(CGP) rates. 
Methods: We retrospectively reviewed the clinical course, anatomic sites of revision, and 
type of revision performed on 67 grafts in 58 patients who underwent at least one revision 
from 1991 to 1995. Results were assessed with regression analysis and Kaplan-Meier 
estimates of  CGP rates (p < 0.05 was considered significant). 
Results: Sixty-seven vein grafts underwent revision of 112 anatomical sites in 95 opera- 
tions. Forty-nine of  67 grafts were single-segment greater saphenous vein grafts and 18 
were composite (>1 segment) grafts, with an overall 5-year CGP rate of 72%. No 
difference was observed between the 4-year CGI? rate in grafts with hemodynamicaliy 
significant distal anastomotic stenoses repaired primarily with jump grafts (n = 20, 71% 
CGP rate) and those with stenoses found only in the graft body (n = 41, 89% CGP rate). 
Vein patch angioplasty was used primarily, but not exclusively, for focal graft body 
stenoses (n = 35), whereas interposition grafts (n = 11) were reserved for more diffuse 
strictures; no significant difference in 3-year CGP rates was observed (94% and 73%, 
respectively). 
Conclusion: Using an appropriate r vision strategy that favors vein patch angioplasty for 
graft body lesions and jump grafts for distal anastomotic lesions, acceptable assisted 
patency rates can be achieved in grafts that are at risk for repeated failure. (J Vase Surg 
1996;24:909-19.) 
The concept of  the failing autogenous infraingui- 
hal bypass graft is now well accepted by vascular 
surgeons, whose task it is to identify the stenofic but 
still patent graft and revise it before thrombosis oc- 
curs. Thrombosis, even with early thrombectomy or
lyric therapy followed by revision, portends reduced 
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graft longevity) -3 Once the failing vein graft is iden- 
tiffed and well characterized with respect o clinical, 
hemodynamic, and anatomic data, the vascular sur- 
geon must choose the appropriate operation to main- 
tain graft patency. Although there have been numer- 
ous reports that have documented that vein graft 
revision enhances the primary patency rates of both in 
situ and reversed saphenous bypass grafts, 4-9 specific 
strategies that address anatomic disease and technical 
management of graft failure have been limited. The 
purpose of  this study was to review our experience 
with a cohort of  58 patients who underwent at least 
one revision o f  a failing or failed but salvageable 
infrainguinal autogenous lower extremity bypass 
graft. This study is designed to characterize the ana- 
tomic causes of  graft failure and outline our experi- 
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Table I. Clinical presentation and 
noninvasive laboratory evaluation of 67 lower 
extremity vein grafts before 95 surgical 
revisions (67 primary and 28 
secondary revisions) 
Peak systolic flow 
velocity 
No. of 
Symptoms revisions ABI Midgraft Stenosis 
Asymptomatic 24 0.8 -+ 0.04 55 -+ 5 371 _+ 29 
Claudication 34 0.8 -+ 0.03 61 -+ 6 314 -+ 17 
Rest pain or 37 0.4 _+ 0.03* 45 -+ 5 348 -+ 42. 
tissue loss 
*p < 0.02. 
ence with several different revision strategies for graft 
salvage. 
METHODS 
During the 5-year period from January 1991 to 
December 1995, 58 patients underwent surgery for a 
failing or failed(opened by thrombectomy or lyric 
therapy) autogenous infrainguinal bypass grafts at 
New England Medical Center. Sixty-seven grafts 
were revised at least once, whereas 23 were revised on 
two or more occasions, for a total of 95 revisions. 
Patent grafts with impending failure (56 of 67 grafts) 
were studied angiographically when graft deteriora- 
tion was identified by clinical or noninvasive labora- 
tory evaluation. Clinical deterioration was suspected 
ifa history of symptom progression was reported or if 
physical examination revealed a change in the graft or 
distal pulse quality. Graft deterioration i both symp- 
tomatic and asymptomatic patients was further eval- 
uated with segmental rterial Doppler pressure mea- 
surements and pulse volume recordings before and 
after exercise. An decrease in ankle-brachial index 
more than 0.15 was considered significant enough to 
warrant further graft evaluation. Surveillance duplex 
ultrasonographic s ans (ATL, HDI System, Bothell, 
Wash., L10-5 MHz probe) of the entire graft were 
performed when graft deterioration was suspected or 
as part of routine postoperative surveillance, unless 
the clinical situation or an abnormally low anlde- 
brachial index dictated arteriographic evaluation. 
Peak systolic flow velocity was measured at multiple 
points on the graft, focusing on suspected stenotic 
areas. A peak systolic flow velocity greater than 300 
cm/sec in an asymptomatic l mb represented a graft- 
threatening stenosis and prompted an arteriographic 
scan in most instances, unless the patient was medi- 
cally unfit for surgery or autogenous tissue was tin- 
available for graft revision. Because ofindMdual sur- 
geon preference for the graft surveillance method as 
well as variations in patient compliance, 63% of grafts 
underwent duplex scans before the first revision, 
whereas 75% of grafts that were revised more than 
once were scanned before surgery. Thirty-one per- 
cent of grafts were studied with pulse volume record- 
ings and segmental arterial pressure measurements 
alone before the arteriographic s an and revision. 
Of the 67 original grafts that underwent revision, 
49 Were single-segment greater saphenous vein 
grafts, including 31,in situ grafts, 15 nonreversed 
translocated grafts, and three reversed grafts. Eigh- 
teen were composite grafts (more than one scgment) 
spliced with arm vein only (10), greater saphenous 
vein (5), lesser Saphenous vein (1), or some combi- 
nation of these (2). The initial bypass graft was to the 
above-knee popliteal artery in five limbs, the below- 
lmee popliteal artery in 16 limbs, and to the tibial 
vessels in 46 limbs. 
Graft failure in the occluded bypass grafts that was 
detected at the time of the first revision (11 of 67 
grafts) was heralded by a return to, or worsening of, 
prebypass symptoms and arterial pressures, as well as 
a loss of graft pulse. Graft thrombosis was confirmed 
either by Duplex scan, by a standard angiogram, or 
both, with expedient selective use oflytic therapy or 
prompt hrombectomy to open the graft and identify 
an anatomic reason f r failure. Data were collected by 
reviewing the hospital records, including noninvasive 
laboratory studies, angiograms and reports, and op- 
erative notes, as well as by personal interviews during 
follow-up (reviewed in Table I). Details of the gross 
pathologic haracter of the lesions that were respon- 
sible for impending raft failure were gleaned primar- 
ily from operative notes and wcre sufficient for char- 
acterization of these lesions in 81 of 95 revisions. 
The secondary operations that were used to cor- 
rect 112 anatomic lesions in 95 operations included 
vein patch angioplasty (VPA; 60) for focal lesions 
(<2 cm), vein interposition grafts (graft, 15), vein 
jump grafts (25), polytetrafluorocthylene patch an- 
gioplasty (6), balloon angioplasty (6), or some com- 
bination of these (14). A jump graft is an auto genous 
extension of the bypass from the normal vein graft 
proximal to a stenosis to nondiseased distal native 
artery. 
The mean follow-up period for this group of 67 
grafts was 39 months from the original operation and 
25 months from the first revision. Cumulative graft 
patency (CGP) rates, patient survival rates, and limb 
salvage rates were calculated using life-table analy- 
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Table II. Anatomic location of 112 vein graft stenoses identified before revision and method used to 
correct hem 
Repair 
Site of primary revision No. of lesions VIA IP graft Jump graft PTFE patch PTA 
Proximal anastomosis 5 1 
Distal anastomosis 15 5 
Midgraft 49 37 8 
Native artery 6 2 
Site of secondary evision 
Proximal anastomosis 5 1 
Distal anastomosis 5 2 
Midgraft 10 5 4 
Venovenostomy 4 4 
Vein patch 6 3 2 
Native artery 7 1 
Total 112 60 15 
3 I 
!0 
3 1 
2 2 
1 3 
3 
1 
1 
4 
25 6 
IPgraft, Interposition graft; PTFE, polytetrafluoroethylene patch angioplasty; PTA, percntaneous transluminal ngioplasF. 
sis. 1° Limb salvage rates were expressed in terms of 
clinically functional limbs. The statistical analysis was 
performed with Stat View 4.5 statistical software 
(Abacus Concepts, Berkeley, Calif.). Kaplan-Mcier 
life-table stimates were constructed with differences 
between groups assessed using a proportional haz- 
ards regression analysis. Comparisons of group char- 
acteristics were performed using analysis of  variance 
with Newman-Keuls post hoc testing (p value less 
than 0.05 was considered significant). 
RESULTS 
The anatomic location of 112 infrainguinal by- 
pass graft or native arterial lesions that underwent 95 
revisions and the type of revision performed are re- 
viewed in Table II. The majority of the revisions were 
performed for lesions that were confined to the con- 
duit, excluding the anastomoses (69 of 112, 62%). 
Forty-nine of 69 midgraft conduit lesions were re- 
paired at the first revision, whereas 20 were addressed 
at subsequent secondary revisions. VPA was the most 
commonly performed operation; it was used to cor- 
rect 57 vein graft stenoses and three native artery 
lesions. Seven of thc 60 VPAs were performed on 
lesions at the distal anastomosis, three of which were 
at the ankle level. Twenty-seven percent of  the lesions 
corrected in 23 re-revisions were at sites of  previous 
VPA or venovenostomy, whereas 46% were new sec- 
ondary lesions that did not involve an anastomotic 
site, 
Gross pathologic lesions that were responsible for 
the failing graft and the interval to revision are de- 
picted in Fig. 1. Although some grafts at the time of 
revision had more than one site ofstenosis, this graph 
reflects the predominant lesion that was responsible 
for impending failure or thrombosis. [ntimal hyper- 
plasia was identified as the primary cause of graft 
stenosis in 63 intrinsic stenoses, including 23 proxi- 
mal and distal anastomotic lesions and 40 midgraft 
lesions that developed de novo or at valve sites or sites 
of previous venovenostomy. M1ten proximal anasto- 
motic stenoses occurred in nonreversed saphenous 
vein grafts. Progression of atherosclerosis contrib- 
uted to graft failure, with 18 treatable lesions identi- 
fied. Thirteen stenoses were located in the native 
arterial circulation; five were attributed to late athero- 
sclerotic progression i  the vein graft itself. The in- 
terval to revision in grafts that failed because of native 
artery progression of atherosclerosis was significantly 
greater than in grafts that failed for any other reason 
(p < 0.05). Seven of the 67 grafts had two or more 
intrinsic stenoses in separate areas of the midgraft 
(excluding the anastomoses). Eleven of the 67 grafts 
were occluded at the time of  first revision, and two 
additional occlusions occurred after the first revision. 
Nine of these 13 occluded grafts were opened with 
uroldnase, and the remaining four grafts underwent 
thrombectomy in the pefioperative period. Six of  
these 13 grafts have remained patent at the last fol- 
low-up, with two grafts remaining open at 48 
months. 
The overall CGP rate by life-table analysis (Fig. 2 
and Table III) for the 67 grafts that underwent at 
least one revision was 72% at 5 years. The CGP rates 
of grafts that were originally constructed as multiseg- 
ment composite grafts was 56%, compared with a 
95% rate for single-segment greater saphenous vein 
grafts at 30 months (Fig. 2 and Table IV; p < 0.05). 
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Fig. 1. Comparison of causes of infrainguinal autogenous bypass graft failure leading to 
revision and time interval from original bypass to discovery of graft failure. Vein graft failure 
caused by progression of atherosclerosis'occurred later than failure associated with other causes. 
*p < 0.05 by analysis of variance. 
The CGP rate of grafts that required correction of a 
distal anastomotic stenosis at some point during the 
life of the graft was 71% at 4 years, whereas grafts that 
underwent graft body revision alone had a 89% CGP 
rate at 4 years (Fig. 3 and Table V; p = NS). Graft 
body stenoses that were repaired with one or more 
VPA procedures had a 3-year CGP rate of 94%, 
whereas those repaired with interposition grafts had a 
CGP rate of 73% at 3 years, with no significant 
difference in patency rates noted. The 4-year CGP 
rate for grafts that were revised with a distal jump 
graft was 83%. The 3-year secondary assisted patency 
rate for the entire group of 67 grafts was 70% (data 
not shown). 
The perioperative morbidity rate for the 95 vein 
graft revisions was 9%. Wound complications devel- 
oped in three patients, and there were three minor 
bleeding complications that were related to perioper- 
ative heparin use. Two patients had myocardial in- 
farction without hemodynamic compromise. A graft 
infection with hemorrhage from a dehisced proximal 
anastomosis developed in one patient and resulted in 
graft failure and amputation. The overall limb salvage 
rate for patients who underwent revision procedures 
was 83% at 5 years, and the 5-year survival rate after 
the first revision was 72%. 
DISCUSSION 
Since the introduction of the autologous aphe- 
nous vein bypass for lower extremity ischemia by 
Kunlin in 1948, a great deal has been learned about 
the natural history of the arterialized venous conduit. 
In 1973 Szilagyi et al. u characterized six important 
morphologic alterations that are observed anglo- 
graphically, as well as in postmortem and surgical 
pathologic vein graft specimens. In this landmark 
study, they found that intimal thickening (neointimal 
hyperplasia) was the most common abnormality con- 
tributing to graft failure, which he described as "wavy 
narrowing" that diffusely involved extensive portions 
of grafts. He also described the fibrotic valve and 
traumatic stenosis, which we now know are both also 
related to neointimal hyperplasia n response to local 
graft flow disturbance or intimal trauma. 12 Athero- 
sclerotic degeneration, typical of the native artery, 
that contributed to graft failure was observed as a late 
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Fig. 2. Cumulative primary assisted patency data of 67 
infrainguinal autogenous bypass grafts that underwent at 
least one revision (upper panel). CGP rates of 49 greater 
saphenous vein versus multiple vein segment lower extrem- 
ity bypass grafts were 95% and 86% at 30 months (p < 0.05) 
(lower panel). 
finding in 8% of grafts, but interestingly, it was ob- 
served histologically in 80% of specimens that were 
taken from grafts that had been in place 2 years or 
longer. The other two less common entities were 
suture stenosis at vein branches and late aneurysmal 
degeneration of the vein. Nowhere in SzilagTi's 
study, however, is there mention of anastomotic ste- 
nosis as a cause of  vein graft failure. 
In 1981 Whittemore t al.1 reported 109 femo- 
ropopliteal vein graft failures in which vein graft 
stenosis was the most common cause of failure. In 
that report he highest CGP rate was achieved in the 
grafts that had short-segment sterioses repaired with 
VPA before graft thrombosis: 86% versus i9% 5-year 
CGP rates in grafts that required thrombectomy. 
Subsequent reports have shown that VPA performed 
for focal stenoses in patent grafts is superior to per- 
cutaneous transluminal angioplasty. 2,s In 1992 
Berkowitz et al.6 reported anatomic data in a series of 
reversed saphenous vein graft stenoses in which the 
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Fig. 3. Comparison of 4-year cumulative patency data of 
grafts revised for midgraft versus distal anastomotic stenosis 
regardless of method used for revision. 
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Fig. 4. Life-table analysis of failing or failed lower extrem- 
ity vein grafts that underwent revision with either VPA, 
interposition graft, or jump graft, 
majority of lesions (40%) were just distal to the prox- 
imal anastomosis hood and 29% were juxtaanasto- 
motic, evenly split between proximal and distal. The 
propensity for proximal midgraft lesions in their se- 
ries may have been a result of the natural tapering of 
the saphenous vein proximally when placed in the 
reversed position. Sanchez et al.8 reported their ob- 
servations with 72 falling vein grafts in a series of  120 
infrainguinal reconstructions m which thev observed 
a strikingly low 9% juxtaanastomotic stenosis inci- 
dence. Their conclusion was that perhaps undetected 
anastomotic stenosis favors enhanced graft thrombo- 
sis, which accounts for a disproportionate loss of 
grafts that have these lesions. 
A report by Donaldson ct al.7 detailed the causes 
of primary failure of  85 in situ bypass grafts and found 
that 63% of graft thromboses were caused by intrinsic 
graft lesions, 27% by juxtaanastomotic lesions, and 
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Tab le  I I I .  Cumulat ive patency data for greater saphenous and composite vein bypass grafts 
Interval No. of grafts No. of failed No. of grafts Interval patency Cumulative patency Standard 
(mo) at risk grafts withdrawn rate (%) rate (%) error (%) 
0-3 67 1 0 98 98 1.5 
3-6 63 0 3 100 98 1.5 
6-12 58 1 4 99 97 2.2 
12-18 55 0 7 100 97 2.2 
18-24 46 0 7 100 97 2.2 
24-30 36 2 5 95 92 3.8 
30-36 28 2 6 95 87 5.0 
36-42 24 1 3 ~7 84 5.9 
42~48 15 0 9 100 84 5.9 
48-54 12 2 1 88 72 9.0 
54-60 11 0 1 100 72 9.0 
Tab le  IV ,  A.  Cumulat ive graft patency data for greater saphenous, bypass grafts undergo ing revision 
Interval No. of grafts No. of ailed No. of grafts Interval patency Cumulative patency Standard 
(mo) at risk grafts withdrawn (%) (%) error (%) 
0-3 49 1 0 98 98 2.0 
3-6 47 0 1 100 98 2.0 
&12 44 0 3 100 98 2.0 
12-18 41 0 3 100 98 2.0 
18-24 37 0 4 100 98 2.0 
24-30 30 1 6 97 95 3.5 
30-36 25 0 5 100 95 3.5 
36-42 21 1 3 96 91 5.4 
42-48 15 0 6 100 91 5.4 
48-54 12 2 1 88 79 9.2 
54-60 11 0 1 100 79 9.2 
Tab le  IV ,  B. Cumulat ive graft patency data for mult iple vein segment bypass grafts 
undergo ing revision 
Interval No. of grafts No. of failed No. of grafts Interval patency Cumulative patency Standard 
(mo) at risk grafts withdrawn (%) (%) error (%) 
0-3 18 0 0 100 100 0.0 
3-6 16 0 2 100 100 0.0 
6-12 15 1 0 94 94 6 
12~18 12 0 3 100 94 6 
18-24 9 0 3 100 94 6 
24-30 6 1 2 89 83 10 
30-36 3 2 1 73 56 15 
36-42 2 0 1 100 56 17 
36% by midgraft  lesions that were not  specifically 
related to technical errors. Mills ~s prospectively stud- 
ied 227 infrainguinal reversed vein grafts over a 
5-year per iod and found 33 intrinsic graft stenoses in 
29 compromised grafts, o f  which the major ity (53%) 
were juxtaanastomotic,  and only 29% of  the lesions 
were in the middle port ion  o f  the graft. In 1991 
Bandyk et al. ~4 reported his experience with vein graft 
revision in a series o f  83 infrainguinal saphenous 
bypass grafts, 94% of  which were in situ reconstruc- 
tions. The most  common cause o f  graft failure was 
intrinsic graft stenosis, which usually developed 
within the first year after surgery. The distr ibut ion o f  
stenoses in this predominant ly  nonreversed saphe- 
nous graft series was 31% juxtaanastomotic,  45% 
midgraft,  and 24% native artery progression. Bandyk 
also reported a 21% restenosis rate after V IA  and 
concluded that interposit ion grafting may be a more 
durable opt ion.  In  that report,  however, VPA was 
used for only 31 revisions and 15 were at an anasto- 
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Table  V, A. Cumulative patency data for lower extremity autogenous bypass grafts undergoing 
revision for midgraft anastomotic stenoses 
Interval No. of grafts No. of failed No. of grafts Interval patency Cumulative patency Standard 
(too) at risk grafts withdrawn (%) rate (%) error (%) 
0-3 41 0 0 100 100 0 
3-6 39 0 2 100 100 0 
6-12 35 1 3 97 97 2.7 
12-18 31 0 4 100 97 2.7 
18-24 27 0 4 100 97 2.7 
24-30 20 1 6 96 93 4.7 
30-36 15 1 4 96 89 &4 
36-42 13 0 2 100 89 6.4 
42-48 8 0 5 100 89 6.4 
48-54 6 1 1 88 77 11 
54-60 5 0 1 100 77 11 
Tab le  V, B. Cumulative patency data for lower extremity autogenous bypass grafts undergoing 
revision for distal anastomotic stenoses 
Interval No. of grafts No. of failed No. of grafts Interval patency Cumulative patency Standard 
(too) at risk grafts withdrawn (%) (%) error (%) 
0-3 20 1 0 100 95 4.9 
3-6 18 0 1 100 95 4.9 
6-12 17 0 1 97 95 4.9 
12-I8 16 0 1 100 95 4.9 
18-24 14 0 2 100 95 4.9 
24-30 12 1 6 96 88 8 
30-36 10 1 1 96 81 10 
36-42 7 1 2 100 71 13 
42-48 4 0 3 100 71 13 
Tab le  VI .  Cumulative patency data for lower extremity autogenous bypass grafts revised with vein 
patch angioplasty 
Interval No. of grafts No. of failed No. of grafts Interval pateney Cumulative patency Standard 
(too) at risk grafts withdrawn rate (%) rate (%) error (%) 
0-3 35 1 0 97 97 2.8 
3-6 33 0 1 100 97 2.8 
6-12 29 1 3 97 94 4.1 
12-18 26 0 3 100 94 4.1 
18-24 22 0 4 100 94 4,1 
24-30 17 0 5 97 94 4.1 
30-36 16 0 1 100 94 4.1 
36-42 13 1 2 93 87 7.5 
42-48 9 0 4 100 87 7.5 
48-54 6 0 3 100 87 7.5 
54-60 5 0 1 100 87 7.5 
motic stenosis. In  addition, jump or sequential grafts 
had a high failure rate (52%), although the majority of 
these revisions were to tibial vessels at the ankle level. 
In  our study of 95 operations to correct 112 
anatomic stenoses in 67 infrainguinal autogenous 
reconstructions, we have demonstrated that an ag- 
gressive surgical approach to the failing or failed vein 
graft can be rewarded with durable results, although 
higher-risk composite grafts are generally at a disad- 
vantage from the outset. Our  philosophy of  vein graft 
revision has generally been to correct simple lesions 
simply, favoring an approach that conserves conduit  
when possible without compromising the quality of 
the operation. It has been our policy to construct the 
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original bypass grafts and leave the graft in the sub- 
cutaneous position (94% of grafts reported) to facili- 
tate vein graft surveilhnce and repair. In addition, we 
favor the early use of postoperative anticoagulation 
therapy (used in 89% of secondary revisions), which 
may account for the fact that only eight of 37 grafts in 
patients who had rest pain or tissue loss were oc- 
cluded. VIA was the most frequently performed re- 
vision operation, comprising 53% of the repairs in this 
series. Focal stenoses that were amenable to VIA 
comprised 71% of the midgraft lesions observed, 
compared with 27% that were more diffuse and re- 
quired jump or interposition grafts. These midgraft 
lesions were predominantly neointimal hyperplastic 
in nature and appeared within 6 to 18 months, in 
contrast to the atherosclerotic midgraft stenoses (7%) 
that appeared later (Fig. 1). Vein grafts that under- 
went VIA as the sole method of revision during the 
life of the graft had an 87% CGP rate. We observed 
only 6 recurrences after 60 VPAs, for a 10% recur- 
rence rate. Two recurrences were successfully treated 
with a second vein patch, whereas a third stenosis 
recurred asecond time and went on to undergo and 
interposition grafting procedure. Stenosis in one dis- 
tal anastomotic vein patch recurred and was corrected 
with a distal jump graft. When life-table analysis was 
applied to grafts that underwent VIA compared with 
those that underwent interposition grafting proce- 
dures, no significant difference in the CGP rate was 
observed (Fig. 4). Although the graft lesions that 
were treated with VPA rather than interposition 
grafts were more focal in nature thai the more diffuse 
hyperplasia in the latter; grafts revised with either 
method had reasonable patency rates in line with 
previous reports. 7,9,1316 Jump grafts had an 83% 
CGP rate when they were used predominantly for 
distal anastomotic stenoses, inspite of the fact that six 
of the 25 procedures were performed for associated 
progressive distal atherosclerotic disease. Although 
Bandyld 4 has reported a high failure rate for jump 
grafts constructed from cephalic vein, nine of the 25 
jump grafts in this review were single-segment or
composite arm vein reconstructions, usually of me- 
dian basilic vein. Of these nine grafts, two failed 
within 24 months, one required a subsequent vein 
patch, and four have remained patent beyond 30 
months. We have increasingly favored the use of jump 
grafts over VIA for distal anastomotic stenoses be- 
cause the exposure of the distal target artery through 
unscarred tissue planes is technically simpler and less 
morbid, especially at the tibial level. Obviously this 
strategy depends on conduit availability as well as the 
distal stenosis level. 
This study reaffirms the value of regular clinical 
and noninvasive laboratory follow-up of lower ex- 
tremity vein grafts, as 25% of the limbs studied were 
completely asymptomatic at the time of threatened 
vein graft revision. Our policy with respect o vein 
graft stenosis has been an aggressive one, tending 
toward early revision if the patient is medically fit and 
has autogenous tissue available. This study demon- 
strates that a revision strategy that favors VPA for 
focal midgraft stenoses, vein interposition for diffuse 
midgraft stenoses, and jump grafts for distal anasto- 
motic and native artery stenoses can provide accept- 
able graft patency and limb salvage rates with reason- 
able morbidity and mortality rates (Table VI). 
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DISCUSSION 
Dr. Daniel B. Walsh (Lebanon, N.H.). We have just 
heard an analysis of the 5-year experience in graft salvage of 
a thoughtful group of vascular surgeons. They are seeking 
the most appropriate operation to prevent or overcome 
graft failure. This retrospective analysis examines the expe- 
rience of 58 patients who underwent 95 operations to 
correct 112 anatomic lesions. The patients and the lesions 
compared are an issue. Are the small groups comparable? Is 
there enough material for statistical power? Is lesion behav- 
ior independent of patient characteristics? As with all our 
experiences, the problem is separating fact from variation. 
Clearly this study demonstrates again the necessity for 
regular quantitative follow-up of lower extremity vein 
grafts. This study also confirms what Dr. Dennis Bandyk 
has taught us: revise vein grafts before they fail and your 
long-term limb salvage mad graft patency rates will improve. 
There is a cost, however. The perioperative morbidity rate is 
9%, and hemorrhagic complications occur in 3% of patients. 
The authors have adopted a strategy of repair of focal 
lesions. My own experience agrees. Repair of defects and 
failing vcin grafts is appropriate. I worry, however, that 
sacrificing one iong piece of vein by periodic resections for 
interposition grafts and angioplasty procedures after lysis of 
a failed graft does not yield the longevity of graft patency 
that is provided by total graft replacement with an available 
venous conduit of suitable length. 
My question to the authors is, when a suitable length of 
replacement graft is available and a bypass graft has failed, 
do  they prefer whole-graft replacement or would they opt 
for lysis or  thrombectomy and replacement of a segmental 
lesion? For me, this remains a most difficult clinical ques- 
tion. I would be eager to hear the authors' opinion. 
Dr. Theodore R. Sullivan, Jr. I think that the answer 
to the question of whether to perform whole-graft replace- 
ment versus revision obviously depends on a number of 
issues. First, is the graft thrombosed or is it patent but on 
the verge of failure? That's clearly a big distinction. Dr. 
Whittemore and other investigators have shown that graft 
salvage after thrombectomy of a thrombosed graft is mark- 
edly reduced. Dr, Belkin from the same institution has 
subsequently shown that opening a thrombosed graft with 
lytic therapy also has inferior patency compared with failing 
grafts that are revised before thrombosis. However, we do 
use these maneuvers when we have patients whose grafts 
have failed and we do not have an available conduit for a 
replacement bypass. This issue of conduit availability does 
come up fairly frequently, in that 38% of the patients in this 
study had had previous saphenectomy for a number of 
reasons. In addition, because we are a tertiary referral 
center, patients frequently come to us having had numer- 
ous bypass attempts or failures and have no greater saphe- 
nous vein available. In those instances, we resort o arterial 
reconstruction with arm vein and lesser saphenous vein, 
and rarely polytetrafluoroethylene. 
If the patient has had a failed vein graft that is throm- 
bosed and there is an available saphenous vein in the other 
leg, we will definitely use it, provided that the other leg isn't 
critically ischemic as well. That is sometimes a very difficult 
call to make. On the other hand, if we have a patient who 
has a hemodynamically significant focal stenosis, that is a 
relatively simple problem to fix with a vein patch or a 
limited interposition graft. We would obviously pelfform 
the simple repair first using arm vein or a saphenous vein 
branch before sacrificing the entire contralateral saphenous 
vein. So it really depends on the extent of the lesion, and 
whether the graft is thrombosed. 
Dr. Frank J. Veith (Bronx, N.Y.L Did you separate 
the patients whose grafts had lyric therapy and then under- 
went a revision? Because your patency rates overall are so 
good, if you had a large number of these lysed revisions 
then your results would differ greatly from what most of us 
observe, that is. that these are not very favorable grafts and 
do not do well in the long term. So did you separate these 
lysed revised cases and analyze them separately? 
Dr. Sullivan. We had 11 grafts that were thrombosed 
at the time of presentation, and nine of those underwent 
lyric therapy. When we split those out, we had an insuffi- 
cient graft number to obtain statistical significance, but 
anecdotally, the patency results were actually pretty good. 
Six of the nine grafts that had failed and then underwent 
lyric therapy were still open at the last follow-up, and two of 
these were open as far out as 45 months. So we are 
encouraged by this, but I did not report it because the 
results are premature. 
Dr. Dominie A. DeLaurentis (Philadelphia. Pa.L 
Could you tell us the size of the patient pool during that 
5-year period? How many infrainguinal bypass procedures 
were performed? And could you give us the breakdown 
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between in situ and reversed saphenous vein bypass proce- 
dures. I realize that most of your redos here were with in 
situ grafts, but could you give us those two figures? 
Dr. Sullivan. I will clarify that. Ninety-four percent of 
the original bypass graft procedures were reconstructions 
with nonreversed saphenous vein. They were evenly split 
between in situ bypass grafts and nonreversed translocated 
grafts. Reversed saphenous vein bypass grafts only com- 
prised 6% of the grafts in this series, so comparison of these 
two groups is not possible. 
I cannot provide you with an accurate incidence of graft 
revision, because to do that I would need a reliable denom- 
inator. This group of patients who underwent vein graft 
revision over a S-year period was selected from a series of 
infrainguinal reconstructions that were actually performed 
over an 8-year period that both preceded and overlapped 
the study period. In addition, 15% of those patients were 
referred from outside hospitals with failing or failed grafts 
to be revised. Furthermore, a small percentage of the 
patients who developed failing vein grafts did not undergo 
revision of the graft, whether it be for medical or conduit- 
availability reasons, and are not included in our series. So I 
cannot give you an accurate denominator to provide a 
refiable revision rate, although of the original bypass pro- 
cedures performed at our institution, the revision rate is 8%. 
Dr. Thomas S. Riles (New York, N.Y.). I certainly 
would go along with the idea that these stenoses should be 
surgically repaired when identified. I 'm a little curious, in 
the room here with a lot of people who are very enthusiastic 
about endovascular surgery and stents and so forth, that the 
topic hasn't been brought up as to what role these tech- 
niques would play in the treatment of midgraft lesions. 
What is your thinldng on that topic? Perhaps ome of the 
others present would like to discuss that, as well. 
Dr. Sullivan. Dr. Sanchez and Dr. Veith have reported 
data from their institution with favorable results using 
balloon angioplasty on falling lower extremity bypass grafts 
of all sorts, polytetrafluoroethylene included. The interest- 
ing thing about that series was that the majority of the 
lesions on which they were performing balloon angioplasty 
were inflow lesions or lesions near the proximal anastomo- 
sis. Dr. Berkowitz subsequently published an article on 
reversed bypass grafts, and again there was a predominance 
of lesions in the proximal juxtaanastomotic area, and they 
used balloon angioplasty and had very good results. 
We mad our angiographers have been less than enthu- 
siastic about performing balloon angioplasty in this setting 
because the majority of the stenoses that we discover are in 
the middle portion of the graft or at the distal anastomosis. 
It seems logical that these lesions are not going to do as well 
with balloon angioplasty as the proximal native artery or 
proximal anastomosis lesions. In this series, we only had six 
balloon angioplasty procedures total, and five of those were 
performed in conjunction with other surgical procedures. 
So we will use angioplasty selectively for proximal lesions, 
but as far as midgraft stenoses are concerned, we favor 
surgical revision. We think that this is a relatively simple 
procedure to perform and it has durable patency. 
Dr. Henry D. Berkowitz (Philadelphia, Pa.). I rise 
only to comment on performing balloon angioplasty on 
vein graft stenoses, which has achieved only modest success 
in most studies of graft revision. I noticed that you analyzed 
the patency data of intact saphenous grafts separately from 
that of alternative vein grafts. I recently did the same 
analysis with a large series of angioplasty-treated graft ste- 
noses. The cumulative 5-year patency rate of the saphenous 
grafts was 80%, compared with 42% for the alternative vein 
grafts. Furthermore, most of the poor results occurred in 
grafts that had strictures at the site of vein-vein anastomo- 
ses. Careful analysis of data, such as you have done, that 
identifies the subgroups of graft strictures that can be success- 
fully treated without surgery is a valuable contribution. 
Dr. Peter J. Pappas (Newark, N.J.). My Understand- 
ing of performing angioplasty in arteries is that the reason 
why it works is because there is a controlled issection that 
is created, whereas in a vein graft that has intimal hyperpla- 
sia, you get recoil when you dilate the artery because ofthe 
elastic properties of the intimal hyperplastic segment, and 
that's why balloon angioplasty doesn't work. I think the 
issue is whether placing a small coronary-type stent such as 
is often done when performing percutaneous transluminal 
angioplasty with the coronary circulation would be of any 
benefit, and I am not aware of any literature or any studies 
that have looked at that, are you? 
Dr. Sullivan. I am not aware of any data on this issue, 
but I agree with you that after angioplasty ofa hyperplastic 
vein graft stenosis, there is going to be a significant recoil 
effect. However, as soon as you introduce a stent into an 
already diseased vein graft, you are going to get a fairly 
vigorous intimal hyperplastic response. When you take a 
relatively small-diameter vein graft and add to it the hyper- 
plastic reaction around a stent, that is going to compromise 
the lumen diameter. Placing a stent across afocal stenosis in 
a sense burns a bridge for a simple surgical revision with a 
vein patch. 
Dr. Pappas. I was also intrigued when you said that 
there was a 10% incidence ofrestenosis inyour vein patches. 
I have similarly started to find that in the vein patch group, 
I have started to see restenoses as well, and I have noticed 
that some of the other surgeons around the country have 
advocated using interposition grafts rather than vein 
patches. What is the policy at your institution, have you put 
in interposition grafts over vein patches at all? 
Dr. Sullivan. We reserve interposition grafts for more 
diffuse lesions, not for the short focal stenoses that are 
amenable to a vein patch. The reason is that you need a 
reasonable caliber diameter vein to reconstruct an interpo- 
sition graft. To create a vein patch, as long as the vein is 
reasonably healthy, you can use a very small-caliber vein. So 
When vein conservation is the issue, the interposition graft 
is not as good an option, and I think that we have shown 
that the vein patch is just as durable. 
JOURNAL OF VASCULAR SURGERY 
Volume 24, Number 6 Sullivan ct td. 919 
Dr. Michael A. Golden (Philadelphia, Pa.). I have two 
comments. The first is in reference to the reported subop- 
timal long-term performance of vein grafts after occlusion 
and thrombolysis. If a vein graft that has been lysed and 
found to have a focal lesion can be repaired, however, itmay 
be possible to get an extra 2 to 5 years of graft patency out 
of the graft without he loss of much additional vein. Many 
patients do not have another yard of greater saphenous 
vein, and if they do have it, they may need it for a more 
diffuse problem with their bypass graft, where graft replace- 
ment is required, or for contralateral disease. 
The second is in reference to question that was posed 
earlier in the discussion about placing stcnts in vein grafts. 
In saphenous vein aorrocoronary bypass grafts there is an 
experience with balloon angioplasty and stenting. It is not 
exrcnslve and does appear to be associated with some 
problems. However, in patients who have stenotic vein 
grafts after coronary artery bypass grafting procedures, 
angioplasty with stent deployment is a much less invasive 
procedure than repeat sternotomy and graft revision. In 
some instances good short-term results can be achieved 
Stem placement is associated with stimulation of intima! 
hyperplasia and would likely not yield excellent long-term 
results. 
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